CYCCP Cyclacel Pharmaceuticals Inc
- 7.500
- +0.350+4.90%
Cyclacel Pharmaceuticals Inc News
Cyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
10-Q: Quarterly report
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative
Express News | Cyclacel Pharmaceuticals Inc Files for Resale of up to 15.2 Mln Shares by the Selling Stockholders - SEC Filing
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative
12 Health Care Stocks Moving In Friday's Intraday Session
GainersPaxMedica (NASDAQ:PXMD) stock increased by 110.9% to $0.87 during Friday's regular session. The company's market cap stands at $6.4 million. Q32 Bio (NASDAQ:QTTB) shares rose 23.89% to $29.5. T
Icahn Enterprises L.P., Calamos Convertible And High Income Fund, Another 6 Companies Have A High Estimated Dividend Yield
Icahn Enterprises L.P. (IEP), Calamos Convertible and High Income Fund (CHY), John Hancock (HPF) have the highest dividend yield stocks on this list.
Ship Finance International Limited, SSR Mining, Another 5 Companies Have A High Estimated Dividend Yield
A little less 2K companies listed in the Nasdaq and NYSE pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
Q4 2023 Cyclacel Pharmaceuticals Inc Earnings Call
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to Be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
BERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative
Cyclacel Pharmaceuticals Inc To Go Ex-Dividend On January 19th, 2024 With 0.15 USD Dividend Per Share
January 17th - $Cyclacel Pharmaceuticals Inc(CYCCP.US)$ is trading ex-dividend on January 19th, 2024. Shareholders of record on January 22nd, 2024 will receive 0.15 USD dividend per share on Febru
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP）announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on January 4, 2024, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP）announced today that Spiro Rombotis, President & Chief Executive Officer, will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California.
Cyclacel Pharmaceuticals Announces $1.3M Registered Direct Offering Of Of 388,200 Shares At A Price Of $3.315 Per Share And Private Placement Offering Of 7,956 Shares Of Common Stock At A Purchase Price Of $3.315 Per Share
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it has entered into a definitive agreement for the purchase and sale of 388,200 shares of the Company's common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.315 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.
Cyclacel Pharmaceuticals Announces Reverse Stock Split
BERKELEY HEIGHTS, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
BERKELEY HEIGHTS, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative
Analysis
Price Target
No Data
